What is the step‑by‑step procedure and appropriate dose for intramuscular (IM) tranexamic acid administration?

Intramuscular Tranexamic Acid Administration: Dose and Procedure

Critical Clarification: IM Route Is Not Standard for Postpartum Hemorrhage

The evidence overwhelmingly supports intravenous administration of tranexamic acid for postpartum hemorrhage, not intramuscular. The WHO, ACOG, and all major guidelines recommend IV administration exclusively for PPH management. 1, 2, 3

---

Standard IV Protocol (Guideline-Recommended)

Dose and Administration

• Administer 1 g (100 mg/mL) tranexamic acid intravenously over 10 minutes (infusion rate: 1 mL/min) within 3 hours of birth. 1, 2, 3
• A second 1 g IV dose should be given if bleeding continues after 30 minutes or restarts within 24 hours of the first dose. 1, 2, 3
• Critical timing: Effectiveness decreases by 10% for every 15 minutes of delay; administration beyond 3 hours may be harmful. 1, 2, 3

Step-by-Step IV Procedure

1. Verify indication: Clinically diagnosed PPH (>500 mL blood loss after vaginal birth or >1000 mL after cesarean section, or any blood loss compromising hemodynamic stability). 1, 3
2. Check contraindications: Active thromboembolic disease, subarachnoid hemorrhage, severe hypersensitivity to TXA. 4
3. Prepare: Draw up 10 mL of tranexamic acid (1 g total at 100 mg/mL concentration). 1
4. Infuse slowly: Administer IV at 1 mL/min over 10 minutes to avoid hypotension. 1, 2, 4
5. Monitor: Observe for hypersensitivity reactions, visual disturbances, or seizures during infusion. 4
6. Reassess at 30 minutes: If bleeding persists or recurs within 24 hours, give second 1 g IV dose. 1, 2, 3

---

IM Administration: Research Context Only

When IM Might Be Considered

• IM tranexamic acid is NOT approved or recommended by any guideline for PPH management. 1, 2, 3
• Research suggests IM administration could be useful in pre-hospital trauma or low-resource settings where IV access is unavailable, but this remains investigational for obstetric hemorrhage. 5, 6, 7

IM Dosing (Based on Research, Not Guidelines)

• Research dose: 1 g IM (two 5 mL injections of 500 mg each, one in each injection site) achieves therapeutic levels in 4–11 minutes with bioavailability of 100%. 5, 7, 8
• Alternative higher dose studied in trauma: 30 mg/kg IM (divided between two sites) achieves serum concentrations comparable to IV administration. 6
• Peak concentration occurs at approximately 1 hour after IM injection, compared to immediate peak with IV. 7, 8

Hypothetical IM Procedure (Not Guideline-Endorsed)

1. Prepare two syringes: Each containing 5 mL (500 mg) of tranexamic acid for a total 1 g dose. 5
2. Select injection sites: Use two separate large muscle groups (e.g., bilateral vastus lateralis or deltoids) to optimize absorption. 5, 6
3. Inject deeply: Administer each 5 mL injection into muscle using standard IM technique. 5
4. Monitor injection sites: Mild local reactions (pain, erythema) are common but transient. 5, 7
5. Expect delayed onset: Therapeutic levels (>10 mg/L) reached in approximately 11 minutes, compared to <5 minutes with IV. 5, 7

---

Critical Pitfalls to Avoid

• Never administer TXA intrathecally or into the neuraxial system—this causes seizures. 4
• Do not delay treatment waiting for IV access if IM is your only option in a life-threatening hemorrhage outside a hospital setting—research shows IM achieves adequate levels, though this is off-guideline. 5, 6, 7
• Do not give TXA beyond 3 hours after birth—no benefit is seen and harm is suspected. 1, 2, 3
• Infuse IV TXA slowly (1 mL/min)—rapid bolus causes hypotension. 1, 4
• Do not use IM route if IV access is available—IV is the evidence-based standard. 1, 2, 3

---

Renal Dose Adjustment

• Reduce dose in moderate-to-severe renal impairment (creatinine >250 µmol/L or GFR <30 mL/min), as TXA is renally excreted. 4
• Specific renal dosing: Consult FDA labeling for precise adjustments based on creatinine clearance. 4

---

Concurrent Management

• Always combine TXA with standard PPH management: Oxytocin 5–10 IU (IV or IM), uterine massage, bimanual compression, fluid resuscitation with crystalloids, and escalation to mechanical interventions (balloon tamponade) or surgery as needed. 1, 2, 3
• Avoid concomitant Factor IX or other prothrombotic agents—increases thrombosis risk. 4